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Tumour growth and dissemination are angiogenesis-dependent
processes (Folkman, 1995). One anti-angiogenic strategy targets
known mediators of angiogenesis in specific tumours. In colon
cancer, the over-expression of vascular endothelial growth factor
(VEGF) and its tyrosine kinase receptor correlates with the develop-
ment of metastases (Takahashi et al, 1995). DC101, a monoclonal
neutralizing antibody that targets the mouse VEGF receptor-2 (flk-
1), blocks ligand binding and receptor signaling in vitro, inhibits the
growth and vascularity of tumours in murine models of colon cancer
liver metastasis, and can induce apoptosis of endothelial cells (ECs)
and tumour cells (TCs) in vivo (Bruns et al, 2000a). 
Epidermal growth factor (EGF) is a known regulator of colon
cancer proliferation in vitro, and over-expression of the EGF
receptor correlates with the development of colon cancer metas-
tases (Ciardiello et al, 1999; Radinsky et al, 1995). A recent study
involving use of a humanized chimeric mouse monoclonal anti-
body directed against the EGF receptor (C225) showed that
inhibiting the activity of EGF can induce TC apoptosis in human
colon cancer cells (Liu et al, 2000). 
In addition to liver and regional lymph nodes, colon cancer also
metastasizes to the peritoneal cavity; peritoneal carcinomatosis,
the resulting condition, occurs in 12–20% of patients whose
disease recurs (Copeland et al, 1968; Marcus et al, 1999).
Peritoneal carcinomatosis is associated with significant morbidity
and mortality from the formation of ascites and bowel obstruction.
Given the significant antitumour effect of C225 against colon
cancer cells in vitro and that of DC101 in previous studies of colon
cancer metastases in vivo, we hypothesized that combination
therapy with DC101, which inhibits the VEGF receptor and affects
endothelial cells, and C225, which inhibits the EGF receptor and
affects tumour cells, would be a novel, efficacious therapeutic
strategy against peritoneal carcinomatosis because it targets
several cell types within the tumour microenvironment. 
The primary purpose of this study was to determine the effects
of selective blockade of the VEGF and EGF receptors on tumour
angiogenesis, growth, and ascites formation in a murine model of
human colon cancer peritoneal carcinomatosis. A secondary goal
was to assess whether combination therapy with DC101 and C225
would demonstrate additive or synergistic effects on these vari-
ables. 
MATERIALS AND METHODS 
Reagents and antibodies 
Reagents were obtained as follows: minimal essential medium
(MEM), fetal bovine serum (FBS), penicillin-streptomycin, 
vitamins, sodium pyruvate, L-glutamine, nonessential amino acids,
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trypsin-EDTA, Hanks balanced salt solution (HBSS), and Trypan
blue from Life Technologies, Inc. (Grand Island, NY); 27- and 30-
gauge needles, 1-ml syringes, and Gill 3 haematoxylin from Sigma
Chemical Company (St. Louis, MO); optimum cutting temperature
(OCT) compound from Miles Inc. (Elkhart, IN); diaminobenzidine
(DAB) substrate and Universal Mount from Research Genetics
(Huntsville, AL); Superfrost slides from Fisher Scientific Co.
(Houston, TX); TUNEL kit from Promega (Madison, WI); and 4,6-
diamidino-2-phenylindole dihydrochloride (DAPI) mount from
Vector Laboratories, Inc. (Burlingame, CA). 
Antibodies for immunohistochemical analysis and antiangio-
genic therapy were obtained as follows: rat anti-mouse
CD31/PECAM-1 antibody from Pharmingen (San Diego, CA);
mouse anti-proliferating cell nuclear antigen (PCNA) clone PC10
DAKO A/S from DAKO Corp. (Carpinteria, CA); peroxidase-
conjugated goat anti-rat immunoglobulin (IgG) (H+L) and Texas
Red-conjugated goat anti-rat IgG from Jackson Research
Laboratories (West Grove, PA); peroxidase-conjugated rat anti-
mouse IgG2a from Serotec Harlan Bioproducts for Science, Inc.
(Indianapolis, IN); and rat anti-mouse VEGF receptor-2 mono-
clonal antibody (Prewett et al, 1999; Witte et al, 1998) and
chimeric anti-human EGF receptor monoclonal antibody
(Goldstein et al, 1995) from ImClone Systems, Inc (New York,
NY) (Prewett et al, 1999; Witte et al, 1998). 
Cell culture 
The human colon cancer cell line KM12L4 is a metastatic variant
of KM12C (established from a Dukes stage B2 surgical specimen
of colon cancer) selected by repeated intrasplenic injections in
nude mice (Morikawa et al, 1988). This cell line was the generous
gift of Dr Isaiah J. Fidler (The University of Texas M D Anderson
Cancer Center, Houston, TX). Cells were cultured and maintained
in MEM supplemented with 10% FBS and harvested from subcon-
fluent cultures as described elsewhere (Bruns et al, 2000a). 
Animals and tumour cell inoculation 
Eight-week-old male athymic nude mice (National Cancer
Institute, Animal Production Area, Frederick, MD), caged in
groups of five, were acclimatized for 1 week. Then, each mouse
was given an intraperitoneal injection of 1.0 × 106 KM12L4 colon
cancer cells in 500 µ l of HBSS with a 30-gauge needle attached to
a 1-ml syringe. Mice were then randomized into one of four treat-
ment groups (10 mice per group): control, DC101, C225, or DC101
and C225. All animal studies were conducted under guidelines
approved by the Animal Care and Use Committee of MD Anderson
Cancer Center and UKCCCR guidelines (UKCCCR, 1998).
Administration of antibodies 
Beginning 3 days after injection of tumour cells, mice were given
intraperitoneal (i.p.) injections every third day of either control
vehicle (phosphate buffered saline [PBS]), DC101 (0.8 mg), C225
(1.0 mg), or DC101 (0.8 mg) and C225 (1.0 mg) (each injection
given in a 700-µ l total volume) with a 27-gauge needle attached to
a 1-ml syringe. Mice were weighed weekly. Mice were killed
when the control group became moribund (about 30 days after
therapy began), and complete necropsies were performed, tumour
burden was quantified, and tumours were harvested and analysed
as described below. 
Necropsy and tissue preparation 
Mice were killed by CO2 asphyxiation and weighed. For each
mouse, necropsy was performed, the size of peritoneal tumours
was measured with calipers, the mean tumour size was deter-
mined, and representative lesions were excised. The extent of
ascites was assessed by an investigator who was unaware of the
treatment-group assignment as follows: grade 0, no ascites; grade
1, small ascites; grade 2, moderate ascites; grade 3, large ascites;
grade 4, massive ascites with tense abdomen (Aparicio et al,
1999). Tumour sections were either embedded in OCT compound
and frozen at –70˚C or fixed in formalin and then embedded in
paraffin. 
Immunohistochemical analyses of paraffin-embedded
and frozen tissues 
Tissue sections were treated by standard deparaffinization (for
formalin-fixed and paraffin-embedded tissues) or by fixation in
acetone and chloroform (for tissues frozen in OCT), and immuno-
histochemical analyses were performed as described previously
(Shaheen et al, 1999). Briefly, endogenous peroxidases were
blocked with 3% H2O2 in methanol, and the slides were washed
with PBS, incubated for 20 min in protein-blocking solution (PBS
supplemented with 1% normal goat serum and 5% normal horse
serum), and incubated overnight at 4˚C with primary antibodies
against CD31 or PCNA. Then, the slides were washed, incubated
with protein-blocking solution, incubated for 1 h at room tempera-
ture with peroxidase-conjugated secondary antibodies, washed,
incubated with DAB, washed, counterstained with haematoxylin,
washed, and mounted with Universal Mount and dried on a hot
plate at 56˚C. Frozen sections to be stained for CD31 were incu-
bated with a secondary antibody conjugated to Texas Red (red
fluorescence) instead of the peroxidase-conjugated antibody.
Omission of the primary antibody served as negative control. 
TUNEL assay for apoptotic cells 
Terminal deoxynucleotidyl transferase-(TdT)-mediated dUTP
nick-end labelling (TUNEL) staining was performed according to
the manufacturer’s protocol. Briefly, the sections were fixed with
4% methanol-free paraformaldehyde, washed, permeabilized with
0.2% Triton X-100, washed, incubated with the kit’s equilibration
buffer, incubated with a reaction mix containing equilibration
buffer, nucleotide mix, and the TdT enzyme at 37˚C for 1 h, incu-
bated for 15 min at room temperature with 2 × standard saline
citrate to stop the TdT reaction, washed, stained with DAPI mount
(to visualize the nuclei), and glass coverslips were applied. 
Quantification of CD31 (endothelial cells or tumour
vessels), PCNA (tumour cell proliferation), and
apoptotic cells 
Numbers of tumour vessels and PCNA-positive cells were evalu-
ated by light microscopy (counted in five random 0.159- mm2
fields at 100× magnification), imaged digitally, and processed with
Optimas Image Analysis software (Biscan, Edmond, WA).
Apoptotic cells were visualized with immunofluorescence as
follows. Sections were digitally imaged and processed with Adobe
Photoshop software (Adobe Systems, Mountain View, CA).
CD31-positive ECs were detected by localized red fluorescence by586 RM Shaheen et al
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using a rhodamine filter. Apoptosis was determined by localized
green fluorescence (for TCs) or green with red fluorescence (for
ECs) by using a fluorescein filter. Nuclei were detected by the blue
fluorescence of the DAPI with its filter. Cells were counted in five
consecutive, non- overlapping fields 0.011-mm2 fields per slide at
400× magnification with the first field selected at random in a non-
necrotic portion of the tumour. The percentages of apoptotic ECs
and TCs per field were then calculated as [% apoptotic cells =
(number of apoptotic cells / total number of cells) × 100]. 
Statistical analysis 
All comparisons were tested for statistical significance with the
Mann-Whitney U-test (InStat Statistical Software, San Diego,
CA). P ≤ 0.05 was considered statistically significant. 
RESULTS 
Gross tumour burden and ascites formation 
Body weight at the termination of the experiment was similar in
the treatment and control groups, and no obvious toxic effects
attributable to DC101 or C225 therapy were noted. Necropsy
confirmed the presence of peritoneal metastases in 100% of the
control mice. 
Gross tumour burden was assessed by measuring the diameter
of peritoneal lesions 30 days after therapy was begun (Figure 1A).
Mean peritoneal tumour size was smaller in the DC101 group
(50.3%, P = 0.006) and in the combination DC101 + C225 group
(66.7%, P = 0.001) than in the control group. No differences were
found between the control and C225 groups (P = 0.842) or
between the DC101 and DC101 + C225 groups (P = 0.248).
Although 100% of control and C225 mice had peritoneal disease at
the end of the study, 10% of DC101 mice (1 of 10 mice) and 30%
of the combination-therapy mice (3 of 10 mice) showed no
evidence of disease (not significantly different by chi-square
analysis). 
Ascites was graded on a 0 to 4 scale (Figure 1B). Mean ascites
grade was lower for both the DC101 (66.7%, P < 0.001), and
combination-therapy (100%, P < 0.001) groups than for the
control mice. No difference was found between the control and
C225 groups (P = 0.842). Moreover, the DC101+C225 group had
significantly less ascites than did the DC101 group (P < 0.001);
virtually no ascites was found in the combination-therapy group. 
Tumour cell proliferation 
Tissue sections were also stained for PCNA by immunohistochem-
ical analysis to assess tumour cell proliferation (Figure 2).
Peritoneal tumours were smaller in the DC101 (50.3%, P = 0.006)
and DC101+C225 groups (66.7%, P = 0.001) than in the control
group. No differences were found between the control and C225
groups (P = 0.842) or between the DC101 and DC101+C225
groups (P = 0.248). 
Angiogenesis 
Sections of peritoneal lesions from mice in all four treatment
groups were stained for CD31 immunofluorescence to detect the
number of ECs as a measure of tumour angiogenesis (Figure 3).
Significantly fewer ECs was observed in the DC101 (P < 0.001)
and DC101+C225 groups (P<0.001) than in the control group.
Although no difference was found between the control and C225
groups (P = 0.436), fewer ECs were present in the DC101+ C225
group (41.2%, P < 0.023) than in the DC101 group. 
Apoptosis of tumour cells and endothelial cells 
Immunofluorescent TUNEL staining, with and without concurrent
staining for CD31, was performed on sections of peritoneal metas-
tases to quantify TC (Figure 4A) and EC (Figure 4B) apoptosis.
More apoptotic TCs were observed in the DC101 (14.3-fold,
P<0.001) and DC101+C225 groups (23.6-fold, P< 0.001) than in
the control group. Although no difference was found between the
control and C225 groups (P = 0.796), more apoptotic TCs were
present in the DC101+C225 group (1.7-fold, P = 0.004) than in the
DC101 group. Similar results were found for the number of apop-
totic ECs: More apoptotic ECs were present in the DC101 (226-
fold, P < 0.001) and DC101 + C225 groups (331-fold, P < 0.001)
than in the control group. Although no difference was found
between the control and C225 groups (P = 0.739), more apoptotic
ECs were found in the DC101 + C225 group (1.46-fold, P <
0.043) than in the DC101 group. 
Immunoflurescent images of tumour sections, illustrating the
relative amounts of TC and EC apoptosis, are shown in 
Figure 4C. 
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Figure 1 Effect of DC101 and C225 on gross tumour burden and ascites
formation in mice with colon cancer peritoneal carcinomatosis. (A) Peritoneal
tumours in the DC101 and DC101 + C225 treatment groups were
significantly smaller than those in the control mice (bars, SE; *P < 0.006 vs
control, **P < 0.001 vs control). C225 had no demonstrable anti-tumour
effects when given alone or in combination with DC101. (B) Significantly less
ascites formed in the DC101 and DC101 + C225 treatment groups relative to
that in the control mice (bars, SE; *P < 0.001 vs control; **P < 0.001 vs
DC101). Although C225 did not inhibit ascites when given alone, C225
augmented the effect of DC101 
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DISCUSSION 
Approximately 180 000 new cases of colon cancer are diagnosed
each year in the United States alone, and about half of these
patients eventually develop metastases. Given the prevalence of
colon cancer and the high morbidity and mortality associated with
peritoneal carcinomatosis, finding effective treatments for these
conditions is essential. Recent advances in understanding the
biology of colon cancer metastases have shown that VEGF and
EGF regulate tumour growth, proliferation, and disease progres-
sion (Ciardiello et al, 1999; Liu et al, 2000; Takahashi et al, 1995)
and have made it possible to devise novel biologically based
therapies that may inhibit the activity of mediators of this disease. 
In this report, we used a murine model of human colon cancer
peritoneal carcinomatosis to determine whether selective blockade
of the VEGF receptor-2 (by DC101) or the EGF receptor (by C225)
would alter tumour growth kinetics and affect EC and TC survival.
Treatment with DC101 decreased tumour growth, tumour cell
proliferation and vascularity and significantly increased EC and TC
apoptosis. These findings were consistent with those from another
study done in our laboratory with a CT-26 colon cancer cell line
syngeneic to BALB/c mice (unpublished data, 2000). In that study,
we showed that VEGF is an in vivo EC survival factor for peri-
toneal lesions. In temporal studies, we found that inhibiting VEGF
activity leads to an initial induction of EC apoptosis and, with
continuing therapy, a subsequent induction of TC apoptosis. 
Other recent findings revealed that TC apoptosis of human
colon cancer cells was induced by C225 treatment in vitro (Liu 
et al, 2000). On the basis of these in vitro findings, we hypothe-
sized that administration of C225 in our in vivo model of colon
carcinomatosis would also induce TC apoptosis. However, we
found no significant induction in TC or EC apoptosis from C225
therapy, a finding that contrasts with those of others showing that
C225 led to a decrease in angiogenesis and an associated increase
in TC apoptosis (Bruns et al, 2000b; Perrotte et al, 1999). The
difference in these results probably relates to differences in the
tumour model or system studied. However, in our study, C225 did
potentiate the effects of DC101 by significantly increasing TC and
EC apoptosis relative to that produced by DC101 alone. Our
current findings indicate that an EGF receptor blockade alone is
not sufficient for inducing TC and EC apoptosis in this model, but
in the presence of a VEGF inhibitor (DC101), EGF receptor
blockade can significantly augment DC 101’s induction of TC and
EC apoptosis. 
In addition to potentiating the effect of DC101 on TC apoptosis,
C225 also augmented DC101’s induction of EC apoptosis and its
inhibition of angiogenesis. Since C225 does not effect mouse
EGF-R, it is likely that whatever effect C225 had on the tumours
was indirect, mediated by alterations in the tumour cells them-
selves as stated above. 
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Figure 2 Effect of DC101 and C225 on tumour cell proliferation.
Immunohistochemical staining of peritoneal tumour sections for PCNA (a
measure of tumour cell proliferation) showed that DC101 and DC101 + C225
therapy significantly inhibited tumour cell proliferation (*P < 0.001 vs control).
C225, given alone, did not affect tumour cell proliferation 
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Figure 3 Effect of DC101 on tumour angiogenesis. Immunofluorescent
staining of peritoneal tumour sections for CD31 demonstrated that DC101
and DC101+C225 significantly inhibited tumour vascularity (*P < 0.001 vs
control). C225 did not demonstrate significant antiangiogenic effects when
administered alone but did significantly augment the effect of DC101 
(**P = 0.023 vs DC101 alone). Bars, SEM 
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Figure 4 Effect of DC101 on apoptosis of tumour cells and endothelial cells.
Immunofluorescent staining for (A) TUNEL (TC apoptosis) and (B) sequential
staining for CD31 plus TUNEL (EC apoptosis) were performed in peritoneal
tumour sections and the mean numbers of positive-staining cells (expressed
as a percentage of the total number of cells) were determined. DC101 and
DC101 + C225 therapy significantly increased apoptosis of both TCs and
ECs. Given alone, C225 did not induce apoptosis but significantly augmented
DC101’s induction of both TC and EC apoptosis (by 65.4% and 46.4%,
respectively). (Bars, SEM; *P < 0.001 vs control; **P < 0.043 vs control) 
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Given the 100% tumorigenicity of this model in control mice,
our finding that 10% of the DC101-treated mice and 30% of the
DC101+C225-treated mice had no evidence of disease at the
termination of the study suggests that these mice had a complete
clinical response to therapy. However, this apparent decrease in
tumorigenicity was not borne out in statistical analyses relative to
controls. With regard to the formation of ascites, DC101 and the
combination of DC101 and C225 greatly reduced the extent of
ascites relative to that in the control group (by 66.7% and 100.0%,
respectively). This finding indirectly affirms the potency of VEGF
as a permeability factor (Senger et al, 1990). Others have shown
that anti-VEGF therapy can inhibit vascular permeability induced
by various malignancies (Ke et al, 1996; Zebrowski et al, 1999).
The mechanism by which C225 enhanced the ability of DC101 to
inhibit ascites formation is unknown. 
In conclusion, we have shown that selective blockade of the
VEGF receptor-2 by DC101 significantly decreased tumour vascu-
larity, growth, proliferation, and ascites formation, and increased
EC and TC apoptosis in a relevant model of human colon cancer
peritoneal carcinomatosis. Moreover, tumour vascularity, ascites
formation, and EC and TC apoptosis were successfully augmented
by the concurrent blockade of the EGF receptor by C225. We
conclude that the combined inhibition of VEGF and EGF activity,
a novel biologically based anti-neoplastic therapeutic strategy, has
broad anti-tumour effects that may have clinical utility in
managing peritoneal carcinomatosis in humans. 
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